277 related articles for article (PubMed ID: 30827128)
1. Tocilizumab for the treatment of adult-onset Still's disease.
Castañeda S; Martínez-Quintanilla D; Martín-Varillas JL; García-Castañeda N; Atienza-Mateo B; González-Gay MA
Expert Opin Biol Ther; 2019 Apr; 19(4):273-286. PubMed ID: 30827128
[TBL] [Abstract][Full Text] [Related]
2. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.
Cipriani P; Ruscitti P; Carubbi F; Pantano I; Liakouli V; Berardicurti O; Giacomelli R
Clin Rheumatol; 2014 Jan; 33(1):49-55. PubMed ID: 24005839
[TBL] [Abstract][Full Text] [Related]
4. Adult-onset Still's disease: Advances in the treatment.
Castañeda S; Blanco R; González-Gay MA
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
[TBL] [Abstract][Full Text] [Related]
5. Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.
Vercruysse F; Barnetche T; Lazaro E; Shipley E; Lifermann F; Balageas A; Delbrel X; Fautrel B; Richez C; Schaeverbeke T; Truchetet ME
Arthritis Res Ther; 2019 Feb; 21(1):53. PubMed ID: 30755262
[TBL] [Abstract][Full Text] [Related]
6. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6.
Kadavath S; Zapantis E; Zolty R; Efthimiou P
Int J Rheum Dis; 2014 Mar; 17(3):336-40. PubMed ID: 24581387
[TBL] [Abstract][Full Text] [Related]
7. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.
Perdan-Pirkmajer K; Praprotnik S; Tomšič M
Clin Rheumatol; 2010 Dec; 29(12):1465-7. PubMed ID: 20734215
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
9. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
10. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
[TBL] [Abstract][Full Text] [Related]
11. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
12. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease.
Bannai E; Yamashita H; Kaneko S; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2016; 26(2):297-301. PubMed ID: 24697199
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adult-onset still's disease: up to date.
Yoo DH
Expert Rev Clin Immunol; 2017 Sep; 13(9):849-866. PubMed ID: 28540751
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease.
Yoshida Y; Sakamoto M; Yokota K; Sato K; Mimura T
Intern Med; 2011; 50(16):1757-60. PubMed ID: 21841340
[TBL] [Abstract][Full Text] [Related]
16. Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.
Kobayashi D; Ito S; Murasawa A; Narita I; Nakazono K
Intern Med; 2015; 54(20):2675-9. PubMed ID: 26466710
[TBL] [Abstract][Full Text] [Related]
17. Biologics for the treatment of adult-onset still's disease.
Yoo DH
Expert Opin Biol Ther; 2019 Nov; 19(11):1173-1190. PubMed ID: 31379214
[No Abstract] [Full Text] [Related]
18. Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.
Suzuki S; Kataoka Y; Otani T; Taniguchi Y; Ikeda K; Tamura N; Morimoto S
Clin Rheumatol; 2024 Mar; 43(3):1245-1251. PubMed ID: 38342797
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biological agents in adult-onset Still's disease.
Cavalli G; Franchini S; Aiello P; Guglielmi B; Berti A; Campochiaro C; Sabbadini MG; Baldissera E; Dagna L
Scand J Rheumatol; 2015; 44(4):309-14. PubMed ID: 25656459
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.
Tang KT; Hsieh CW; Chen HH; Chen YM; Chang SH; Huang PH; Lan JL; Chen DY
Clin Rheumatol; 2022 Feb; 41(2):557-566. PubMed ID: 34535869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
